NCT05225363View on ClinicalTrials.gov

Modified Immune Cells (TAG72-CAR T Cells) for the Treatment of Patients With Platinum Resistant Epithelial Ovarian Cancer

PHASE1RecruitingINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

May 5, 2022

Primary Completion Date

October 5, 2026

Study Completion Date

June 5, 2027

Conditions
Platinum-Resistant Ovarian Carcinoma
Interventions
BIOLOGICAL

Chimeric Antigen Receptor T-cells

Receive TAG72-CAR T cells IP

DRUG

Cyclophosphamide

Given IV

DRUG

Fludarabine

Given IV

Trial Locations (1)

91010

RECRUITING

City of Hope Medical Center, Duarte

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER